|
|
Line 3: |
Line 3: |
| <StructureSection load='4p4x' size='340' side='right'caption='[[4p4x]], [[Resolution|resolution]] 1.90Å' scene=''> | | <StructureSection load='4p4x' size='340' side='right'caption='[[4p4x]], [[Resolution|resolution]] 1.90Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[4p4x]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4P4X OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4P4X FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4p4x]] is a 12 chain structure with sequence from [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4P4X OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4P4X FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=MLE:N-METHYLLEUCINE'>MLE</scene>, <scene name='pdbligand=ORN:L-ORNITHINE'>ORN</scene>, <scene name='pdbligand=PHI:IODO-PHENYLALANINE'>PHI</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> |
- | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=MLE:N-METHYLLEUCINE'>MLE</scene>, <scene name='pdbligand=ORN:L-ORNITHINE'>ORN</scene>, <scene name='pdbligand=PHI:IODO-PHENYLALANINE'>PHI</scene></td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4p4x FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4p4x OCA], [https://pdbe.org/4p4x PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4p4x RCSB], [https://www.ebi.ac.uk/pdbsum/4p4x PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4p4x ProSAT]</span></td></tr> |
- | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4p4v|4p4v]], [[4p4w|4p4w]], [[4p4y|4p4y]], [[4p4z|4p4z]]</td></tr>
| + | |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4p4x FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4p4x OCA], [http://pdbe.org/4p4x PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4p4x RCSB], [http://www.ebi.ac.uk/pdbsum/4p4x PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4p4x ProSAT]</span></td></tr> | + | |
| </table> | | </table> |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
Line 23: |
Line 21: |
| </StructureSection> | | </StructureSection> |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
- | [[Category: Nowick, J S]] | + | [[Category: Synthetic construct]] |
- | [[Category: Spencer, R K]] | + | [[Category: Nowick JS]] |
- | [[Category: Amyloid]] | + | [[Category: Spencer RK]] |
- | [[Category: Beta-2-microglobulin]]
| + | |
- | [[Category: De novo protein]]
| + | |
- | [[Category: Dodecamer]]
| + | |
- | [[Category: Macrocycle]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Amyloid diseases such as Alzheimer's disease, Parkinson's disease, and type II diabetes share common features of toxic soluble protein oligomers. There are no structures at atomic resolution of oligomers formed by full-length amyloidogenic peptides and proteins, and only a few structures of oligomers formed by peptide fragments. The paucity of structural information provides a fundamental roadblock to understanding the pathology of amyloid diseases and developing preventions or therapies. Here, we present the X-ray crystallographic structures of three families of oligomers formed by macrocyclic peptides containing a heptapeptide sequence derived from the amyloidogenic E chain of beta2-microglobulin (beta2m). Each macrocyclic peptide contains the heptapeptide sequence beta2m63-69 and a second heptapeptide sequence containing an N-methyl amino acid. These peptides form beta-sheets that further associate into hexamers, octamers, and dodecamers: the hexamers are trimers of dimers; the octamers are tetramers of dimers; and the dodecamers contain two trimer subunits surrounded by three pairs of beta-sheets. These structures illustrate a common theme in which dimer and trimer subunits further associate to form a hydrophobic core. The seven X-ray crystallographic structures not only illustrate a range of oligomers that a single amyloidogenic peptide sequence can form, but also how mutation can alter the size and topology of the oligomers. A cocrystallization experiment in which a dodecamer-forming peptide recruits a hexamer-forming peptide to form mixed dodecamers demonstrates that one species can dictate the oligomerization of another. These findings should also be relevant to the formation of oligomers of full-length peptides and proteins in amyloid diseases.
X-ray Crystallographic Structures of Oligomers of Peptides Derived from beta-Microglobulin.,Spencer RK, Kreutzer AG, Salveson PJ, Li H, Nowick JS J Am Chem Soc. 2015 May 12. PMID:25915729[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Spencer RK, Kreutzer AG, Salveson PJ, Li H, Nowick JS. X-ray Crystallographic Structures of Oligomers of Peptides Derived from beta-Microglobulin. J Am Chem Soc. 2015 May 12. PMID:25915729 doi:http://dx.doi.org/10.1021/jacs.5b01673
|